HBP News Alert Huttig Bldg Products (HBP) 3.20 02/14/2015 01

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 2:33 AM

Huttig Bldg Products (HBP) 3.20 $HBP

Huttig Building Products: Big Upside As U.S. Housing Normalizes
John Rolfe - Seeking Alpha - Thu Feb 12, 9:34AM CST
Huttig Building Products, Inc. (NASDAQ: HBP ) ("Huttig" or the "Company"

is one of the few publicly-traded U.S. housing supply companies whose shares are reasonably priced on the basis of current/trailing earnings. At roughly 13x...
HBP: 3.20 (+0.02)

Quarterly Report Card: Research Reports on Huttig, IAC, Iao Kun Group, ICF, and Ignite Restaurant
PR Newswire - Wed Jan 21, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Huttig (NASDAQ: HBP), IAC (NASDAQ: IACI), Iao Kun Group (NASDAQ: IKGH), ICF (NASDAQ: ICFI), and Ignite Restaurant (NASDAQ: IRG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
HBP: 3.20 (+0.02), IRG: 6.95 (-0.02), ICFI: 38.98 (+0.32), IKGH: 1.13 (+0.01), IACI: 64.60 (+0.96)

Helix Announces Initiation of First Clinical Site for US Study
Marketwire Canada - Mon Dec 22, 3:32PM CST
Helix BioPharma (TSX: HBP) (FRANKFURT: HBP) announced today that its United States Phase I study of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous non-small cell lung cancer ("LDOS001"

has been initiated at The University of Texas MD Anderson Cancer Center in Houston, Texas. Helix also anticipates the participation of two additional sites in the United States. Helix anticipates that the first patient will be enrolled in the LDOS001 study in the first quarter of 2015.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix Announces the Results of Its Annual General Meeting
Marketwire Canada - Thu Dec 18, 4:20PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix"

, a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that its Annual General Meeting (the "Meeting"

was held today as scheduled.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. Announces Q1 Fiscal 2015 Results
Marketwire Canada - Mon Dec 15, 4:21PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2015, ended October 31, 2014.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Comparing The 3 Largest Building Materials Wholesale Companies
Joseph Cafariello - at Seeking Alpha - Mon Dec 15, 9:12AM CST

HBP: 3.20 (+0.02), BXC: 1.05 (-0.06), LPX: 17.44 (+0.42)

Helix BioPharma Corp. to Explore Growth Opportunities
Marketwire Canada - Thu Dec 04, 4:38PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company has begun a comprehensive exploration of growth opportunities available to it.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Huttig Building Products, Inc. Announces Third Quarter 2014 Results
Marketwired - Thu Oct 30, 5:00AM CDT
Huttig Building Products, Inc. (Huttig, or the Company) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today reported financial results for the third quarter ended September 30, 2014.
HBP: 3.20 (+0.02)

Helix BioPharma Corp. Announces Fiscal 2014 Results
Marketwire Canada - Thu Oct 23, 7:35PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2014.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix Reports on Interim Review of the Polish L-DOS47 Monotherapy Study in Non-Small Cell Lung Cancer
Marketwire Canada - Tue Sep 30, 7:31AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed its interim data review of the first eight cohorts of the Company's ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"

.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. Initiates Enrollment for Tenth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Fri Sep 26, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the tenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"

.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland
Marketwire Canada - Thu Sep 25, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at the 2nd Global Life Sciences Conference to be held on October 2, 2014 in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange. The conference is sponsored by WedBush Europe and WDM Capital. Over 100 of Central and Eastern Europe's top life science institutional investors, funds, and analysts are expected to attend the Conference.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...